前列腺癌超低分次放疗的剂量效应递减
结论认为随机试验数据不符合线性二次模型恒定分次敏感性和/或80 Gy以上单调剂量效应。
要点
- 14项随机试验荟萃分析得前列腺癌α/β最佳估计1.6 Gy(95%CI 1.3-2.0 Gy)。
- 生化控制可能在约80 Gy EQD2以上饱和,影响超低分次试验解读。
核心结论
- 随机试验的生化控制数据不符合线性二次模型恒定分次敏感性或80 Gy等效剂量以上单调剂量效应。
研究设计与样本
- 对前列腺癌剂量递增和分次放疗的随机试验进行荟萃分析,共纳入14项随机试验、13384例患者。
- 将5年相对有效性映射到单一参考剂量效应曲线,探究约80 Gy EQD2的剂量效应饱和。
主要发现
- 该偏离线性二次模型的现象也可由生化控制在大约80 Gy以上剂量达到饱和来解释。
关键数值与推荐
- α/β最佳估计值为1.6 Gy(95%CI 1.3-2.0 Gy)。
- 生化控制饱和点约80 Gy EQD2。
临床怎么用
- 未来试验设计及正在进行的超低分次试验解读需考虑α/β非恒定及80 Gy以上剂量效应饱和的可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: More than a decade of randomized controlled trials in prostate cancer has established a positive radiation dose response at moderate doses and a consistently low α/β ratio in the linear quadratic model for moderate hypofractionation. The recently published large randomized trial of ultrahypofractionated prostate cancer radiation therapy adds substantially to our current knowledge of dose response and fractionation sensitivity. METHODS AND MATERIALS: Randomized trials of dose escalation and hypofractionation of radiation therapy were meta-analyzed to yield the overall best estimate of the α/β ratio. Additionally, a putative saturation of dose effect previously reported at approximately 80 Gy EQD2 was investigated by mapping the relative effectiveness assessed at 5 years onto a single reference dose-response curve. RESULTS: Meta-analysis of 14 randomized trials including 13,384 patients yielded a best estimate of α/β = 1.6 Gy (95% confidence interval, 1.3-2.0 Gy) but with highly significant heterogeneity (I2 = 70%, P = .0005). Further analysis indicated an association between increasing dose per fraction in the experimental arm and increasing α/β ratio (slope, 0.6 Gy increase in α/β per Gy increase in fraction size; P = .017). This deviation from the linear quadratic model could, however, also be explained by biochemical control maxing out at doses above approximately 80 Gy. CONCLUSIONS: Biochemical control data from randomized controlled trials of dose-per-fraction escalation in prostate cancer radiation therapy are inconsistent with the presence of a constant fractionation sensitivity in the linear-quadratic model and/or a monotonic dose response for biochemical control beyond 80 Gy equivalent dose. These observations have a potential effect on the optimal doses in future trials and the interpretation of ongoing trials of ultrahypofractionation.
引用
- Vogelius IR, Bentzen SM. Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 31987958. doi:10.1016/j.ijrobp.2020.01.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。